| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BGNE Stock Overview
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide.
BeiGene, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$179.82 |
| 52 Week High | US$426.56 |
| 52 Week Low | US$118.18 |
| Beta | 0.66 |
| 1 Month Change | 4.10% |
| 3 Month Change | 36.57% |
| 1 Year Change | -37.99% |
| 3 Year Change | 23.13% |
| 5 Year Change | 161.52% |
| Change since IPO | 534.96% |
Recent News & Updates
BeiGene, McKesson team up to develop data, tools for US community oncology care
BeiGene (NASDAQ:BGNE) signed a strategic agreement with McKesson's (NYSE:MCK) unit Ontada to improve U.S. community oncology care by developing real-world evidence (RWE) data and tools to help increase access to affordable therapies. The partnership will be led by Ontada and focus on developing and implementing RWE to improve community education on the financial impact and value of oncolytics and improve patient access to oncology medicines, BeiGene said in an Aug. 15 press release. "BeiGene aims to bring 10 molecules per year to the clinic starting in 2023 and, as this research advances, we’re delighted to form this strategic partnership with McKesson, which shares the same vision as BeiGene for improving the care of cancer patients," said Christiane Langer, senior vice president of Global Medical Affairs, ex-China, BeiGene.
Novartis/BeiGene's tislelizumab matches Bayer's Nexavar in survival benefit for liver cancer patients in trial
BeiGene (NASDAQ:BGNE) and Novartis' (NYSE:NVS) tislelizumab met the main goal of being as good as Bayer's (OTCPK:BAYZF) (OTCPK:BAYRY) Nexavar (sorafenib) in improving overall survival (OS) of patients with a type of liver cancer in a phase 3 trial. The study, dubbed RATIONALE 301, evaluated tislelizumab against sorafenib as a first-line therapy in adult patients with unresectable hepatocellular carcinoma (HCC). More than 600 patients in the U.S., Europe, and Asia were in the study. BeiGene (BGNE) said that the the safety profile for tislelizumab was consistent with previous studies and no new safety signals were reported.
Shareholder Returns
| BGNE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.0% | -2.0% | 1.1% |
| 1Y | -38.0% | -23.0% | -9.0% |
Return vs Industry: BGNE underperformed the US Biotechs industry which returned -22.2% over the past year.
Return vs Market: BGNE underperformed the US Market which returned -8.9% over the past year.
Price Volatility
| BGNE volatility | |
|---|---|
| BGNE Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 12.3% |
| Market Average Movement | 7.6% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BGNE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: BGNE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 8,600 | John Oyler | https://www.beigene.com |
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin’s lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company’s clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors.
BeiGene, Ltd. Fundamentals Summary
| BGNE fundamental statistics | |
|---|---|
| Market Cap | US$18.61b |
| Earnings (TTM) | -US$2.01b |
| Revenue (TTM) | US$1.07b |
17.4x
P/S Ratio-9.3x
P/E RatioIs BGNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGNE income statement (TTM) | |
|---|---|
| Revenue | US$1.07b |
| Cost of Revenue | US$1.78b |
| Gross Profit | -US$714.29m |
| Other Expenses | US$1.29b |
| Earnings | -US$2.01b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -19.38 |
| Gross Margin | -66.84% |
| Net Profit Margin | -187.65% |
| Debt/Equity Ratio | 10.7% |
How did BGNE perform over the long term?
See historical performance and comparison